The new program also marks one of the firstif not the firstuse of proteomic technologies in clinical research. Proteomics, or the study of all proteins in living cells, has become a hot area of medical research as scientists develop laboratory tools capable of rapidly scanning cells for hundreds of proteins at once. Until now, most proteomic studies have been geared toward learning how to apply these new tools for research.
Begun in 1997, the initiative is led by Lance Liotta, M.D., Ph.D., chief of the Laboratory of Pathology in NCIs Center for Cancer Research, and Emanuel Petricoin, Ph.D., of the FDAs Center for Biologics Evaluation and Research.
As Petricoin noted, the collaboration has been "extraordinarily productive" to date, as he and his colleagues already have invented or refined several key technologies used in proteomic analysis. Included among their accomplishments is the development of protein microarrayswhich measure the cellular levels of hundreds of proteins at onceand a new artificial-intelligence tool to find protein patterns, or fingerprints, indicative of emerging cancer or drug toxicity.
![]() |
||||
|
Oxford University Press Privacy Policy and Legal Statement |